Literature DB >> 35599254

High DKK3 expression related to immunosuppression was associated with poor prognosis in glioblastoma: machine learning approach.

Myung-Hoon Han1, Kyueng-Whan Min2, Yung-Kyun Noh3,4, Jae Min Kim1, Jin Hwan Cheong1, Je Il Ryu1, Yu Deok Won1, Seong-Ho Koh5, Jae Kyung Myung6, Ji Young Park7, Mi Jung Kwon8.   

Abstract

BACKGROUND: Glioblastoma multiforme (GBM) is an aggressive malignant primary brain tumor. Wnt/β-catenin is known to be related to GBM stemness. Cancer stem cells induce immunosuppressive and treatment resistance in GBM. We hypothesized that Wnt/β-catenin-related genes with immunosuppression could be related to the prognosis in patients with GBM.
METHODS: We obtained the clinicopathological data of 525 patients with GBM from the brain cancer gene database. The fraction of tumor-infiltrating immune cells was evaluated using in silico flow cytometry. Among gene sets of Wnt/β-catenin pathway, Dickkopf-3 (DKK3) gene related to the immunosuppressive response was found using machine learning. We performed gene set enrichment analysis (GSEA), network-based analysis, survival analysis and in vitro drug screening assays based on Dickkopf-3 (DKK3) expression.
RESULTS: In analyses of 31 genes related to Wnt/β-catenin signaling, high DKK3 expression was negatively correlated with increased antitumoral immunity, especially CD8 + and CD4 + T cells, in patients with GBM. High DKK3 expression was correlated with poor survival and disease progression in patients with GBM. In pathway-based network analysis, DKK3 was directly linked to the THY1 gene, a tumor suppressor gene. Through in vitro drug screening, we identified navitoclax as an agent with potent activity against GBM cell lines with high DKK3 expression.
CONCLUSIONS: These results suggest that high DKK3 expression could be a therapeutic target in GBM. The results of the present study could contribute to the design of future experimental research and drug development programs for GBM.
© 2022. The Author(s).

Entities:  

Keywords:  Dickkopf-3; Gene; Glioblastoma multiforme; Survival; Wnt/β-catenin signaling

Year:  2022        PMID: 35599254     DOI: 10.1007/s00262-022-03222-4

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.630


  36 in total

1.  Wnt-mediated endothelial transformation into mesenchymal stem cell-like cells induces chemoresistance in glioblastoma.

Authors:  Menggui Huang; Duo Zhang; Janet Y Wu; Kun Xing; Eujin Yeo; Chunsheng Li; Lin Zhang; Eric Holland; Lutian Yao; Ling Qin; Zev A Binder; Donald M O'Rourke; Steven Brem; Constantinos Koumenis; Yanqing Gong; Yi Fan
Journal:  Sci Transl Med       Date:  2020-02-26       Impact factor: 17.956

2.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

3.  Cancer stemness, intratumoral heterogeneity, and immune response across cancers.

Authors:  Alex Miranda; Phineas T Hamilton; Allen W Zhang; Swetansu Pattnaik; Etienne Becht; Artur Mezheyeuski; Jarle Bruun; Patrick Micke; Aurélien de Reynies; Brad H Nelson
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-17       Impact factor: 11.205

4.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

Review 5.  WNT signaling in glioblastoma and therapeutic opportunities.

Authors:  Yeri Lee; Jin-Ku Lee; Sun Hee Ahn; Jeongwu Lee; Do-Hyun Nam
Journal:  Lab Invest       Date:  2015-12-07       Impact factor: 5.662

6.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016.

Authors:  Quinn T Ostrom; Gino Cioffi; Haley Gittleman; Nirav Patil; Kristin Waite; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2019-11-01       Impact factor: 12.300

7.  Robust enumeration of cell subsets from tissue expression profiles.

Authors:  Aaron M Newman; Chih Long Liu; Michael R Green; Andrew J Gentles; Weiguo Feng; Yue Xu; Chuong D Hoang; Maximilian Diehn; Ash A Alizadeh
Journal:  Nat Methods       Date:  2015-03-30       Impact factor: 28.547

Review 8.  Cancer Stem Cells and Immunosuppressive Microenvironment in Glioma.

Authors:  Qianquan Ma; Wenyong Long; Changsheng Xing; Junjun Chu; Mei Luo; Helen Y Wang; Qing Liu; Rong-Fu Wang
Journal:  Front Immunol       Date:  2018-12-21       Impact factor: 7.561

Review 9.  Role of glioblastoma stem cells in cancer therapeutic resistance: a perspective on antineoplastic agents from natural sources and chemical derivatives.

Authors:  Ana Laura V Alves; Izabela N F Gomes; Adriana C Carloni; Marcela N Rosa; Luciane S da Silva; Adriane F Evangelista; Rui Manuel Reis; Viviane Aline O Silva
Journal:  Stem Cell Res Ther       Date:  2021-03-24       Impact factor: 6.832

10.  Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers.

Authors:  Xinxin Peng; Zhongyuan Chen; Farshad Farshidfar; Xiaoyan Xu; Philip L Lorenzi; Yumeng Wang; Feixiong Cheng; Lin Tan; Kamalika Mojumdar; Di Du; Zhongqi Ge; Jun Li; George V Thomas; Kivanc Birsoy; Lingxiang Liu; Huiwen Zhang; Zhongming Zhao; Calena Marchand; John N Weinstein; Oliver F Bathe; Han Liang
Journal:  Cell Rep       Date:  2018-04-03       Impact factor: 9.423

View more
  1 in total

1.  Identification of genes from ten oncogenic pathways associated with mortality and disease progression in glioblastoma.

Authors:  Myung-Hoon Han; Kyueng-Whan Min; Yung-Kyun Noh; Jae Min Kim; Jin Hwan Cheong; Je Il Ryu; Yu Deok Won; Seong-Ho Koh; Young Mi Park
Journal:  Front Oncol       Date:  2022-08-10       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.